Fort Sheridan Advisors LLC trimmed its holdings in shares of MeiraGTx Holdings plc (NASDAQ:MGTX – Get Rating) by 1.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 105,145 shares of the company’s stock after selling 1,475 shares during the period. Fort Sheridan Advisors LLC owned approximately 0.24% of MeiraGTx worth $1,456,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in MGTX. Nisa Investment Advisors LLC bought a new stake in shares of MeiraGTx during the fourth quarter valued at approximately $41,000. Advisor Group Holdings Inc. bought a new stake in shares of MeiraGTx during the fourth quarter valued at approximately $66,000. Rockefeller Capital Management L.P. increased its position in shares of MeiraGTx by 48.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,600 shares of the company’s stock valued at $109,000 after acquiring an additional 1,500 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of MeiraGTx during the fourth quarter valued at approximately $173,000. Finally, Financial Advisory Service Inc. bought a new stake in shares of MeiraGTx during the fourth quarter valued at approximately $203,000. 67.68% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research firms have commented on MGTX. Piper Sandler cut their target price on shares of MeiraGTx from $40.00 to $30.00 in a research report on Thursday, May 12th. Chardan Capital reaffirmed a “buy” rating and issued a $46.00 target price on shares of MeiraGTx in a research report on Friday, May 13th. Finally, Barclays cut their target price on shares of MeiraGTx from $32.00 to $18.00 in a research report on Friday, May 13th.
Insider Activity at MeiraGTx
MeiraGTx Trading Up 4.2 %
Shares of MGTX stock opened at $10.35 on Friday. MeiraGTx Holdings plc has a 1 year low of $6.59 and a 1 year high of $24.89. The firm has a fifty day moving average price of $8.04 and a 200-day moving average price of $11.24. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.18 and a quick ratio of 2.18. The company has a market cap of $462.75 million, a price-to-earnings ratio of -5.25 and a beta of 1.76.
MeiraGTx (NASDAQ:MGTX – Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.21). MeiraGTx had a negative net margin of 224.55% and a negative return on equity of 47.01%. The business had revenue of $5.63 million for the quarter, compared to the consensus estimate of $9.25 million. As a group, equities analysts predict that MeiraGTx Holdings plc will post -2.33 earnings per share for the current year.
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on MeiraGTx (MGTX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.